Treatment of Glycogen Storage Disease Type IV with Spastic Paraparesis and Skeletal Muscle Spasms
Clinical Scenario
This protocol addresses Glycogen storage disease type IV presenting with spastic paraparesis, skeletal muscle spasms and cramps, and peripheral neuropathy — a neurological phenotype requiring a structured, symptom-focused management approach.
Spastic paraparesis
Skeletal muscle spasms & cramps
Peripheral neuropathy
Key Clinical Features
GSD IV should be suspected in any adult presenting with spastic paraparesis, with or without peripheral neuropathy. The combination of spasticity, muscle cramps, and progressive gait impairment defines the key management priorities for this phenotype.
Treatment Approach — Partial Overview
Management is primarily symptomatic and best coordinated by a multidisciplinary team. Anti-spasmodic therapy plays a central role in addressing skeletal muscle spasms and cramps. As gait impairment progresses, assistive devices become an increasingly important component of the plan. Further pharmacological options and the complete management algorithm are detailed in the full protocol.
Treatment Goals
- Alleviation of skeletal muscle spasms and cramps
- Improved walking speed
References
DOI: 10.1016/j.ymgme.2023.107525
- APBD should be suspected in any adult patient who presents with neurogenic bladder and spastic paraparesis, with or without peripheral neuropathy.
- Treatment of neurologic manifestations in GSD IV, including APBD, are primarily symptomatic and best managed by multidisciplinary teams with specialists dictated by the disease manifestations.
- Anti-spasmodic drugs may alleviate skeletal muscle spasms and cramps.
- As the disease progresses and gait impairment worsens, patient requirements for assistive devices may increase from support with a cane, to walkers, and ultimately to wheelchairs.
- Medications that target nerve signals have been shown to improve walking speed in other demyelinating disorders (i.e., MS) and can be considered for APBD.
View source ↗